Replies to post #198856 on Biotech Values

[DewDiligence]

TXMD +21%/AH on nominal phase-3 success:

http://finance.yahoo.com/news/therapeuticsmd-announces-positive-top-line-210500709.html

I use the word, nominal because none of the four doses met the pre-specified p-value threshold of 0.01 on both co-primary endpoints.